(Q43287918)

English

Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques

scientific article published on 20 August 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Florent F Richy

1

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Soutrik Banerjee

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Yves Brabant

3

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sandra Helmers

4

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

publication date

20 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Epilepsy Behavior

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

240-245

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

The relationship between poor medication compliance and seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Bioequivalence in development of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

New antiepileptic drugs that are second generation to existing antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Extended-release formulations for the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Extended-release formulations in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Pharmacokinetics of levetiracetam XR 500mg tablets

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Indirect comparisons of competing interventions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Benefit-risk assessment of levetiracetam in the treatment of partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Effect of levetiracetam on depression and anxiety in adult epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Topiramate and psychiatric adverse events in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Psychiatric adverse events during levetiracetam therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Network meta-analysis for indirect treatment comparisons

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.07.013

7 January 2021

Identifiers

10.1016/J.YEBEH.2009.07.013

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43287918&oldid=1985597380"